Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1
Background - Immune checkpoint therapy has dramatically changed treatment options in patients with metastatic melanoma. However, a relevant part of patients still does not respond to treatment. Data regarding the prognostic or predictive significance of preexisting immune responses against tumour an...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
5 January 2018
|
| In: |
European journal of cancer
Year: 2018, Jahrgang: 90, Pages: 122-129 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2017.12.001 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.ejca.2017.12.001 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0959804917314570 
|
| Verfasserangaben: | G. M. Haag, I. Zoernig, J. C. Hassel, N. Halama, J. Dick, N. Lang, L. Podola, J. Funk, C. Ziegelmeier, S. Juenger, M. Bucur, L. Umansky, C. S. Falk, A. Freitag, I. Karapanagiotou-Schenkel, P. Beckhove, A. Enk, D. Jaeger |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 167144812X | ||
| 003 | DE-627 | ||
| 005 | 20240323101247.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190815s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2017.12.001 |2 doi | |
| 035 | |a (DE-627)167144812X | ||
| 035 | |a (DE-599)KXP167144812X | ||
| 035 | |a (OCoLC)1341237575 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Haag, Georg Martin |d 1979- |e VerfasserIn |0 (DE-588)133390934 |0 (DE-627)544043863 |0 (DE-576)29981548X |4 aut | |
| 245 | 1 | 0 | |a Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1 |c G. M. Haag, I. Zoernig, J. C. Hassel, N. Halama, J. Dick, N. Lang, L. Podola, J. Funk, C. Ziegelmeier, S. Juenger, M. Bucur, L. Umansky, C. S. Falk, A. Freitag, I. Karapanagiotou-Schenkel, P. Beckhove, A. Enk, D. Jaeger |
| 264 | 1 | |c 5 January 2018 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 15.08.2019 | ||
| 520 | |a Background - Immune checkpoint therapy has dramatically changed treatment options in patients with metastatic melanoma. However, a relevant part of patients still does not respond to treatment. Data regarding the prognostic or predictive significance of preexisting immune responses against tumour antigens are conflicting. Retrospective data suggested a higher clinical benefit of ipilimumab in melanoma patients with preexisting NY-ESO-1-specific immunity. - Patients and methods - Twenty-five patients with previously untreated or treated metastatic melanoma and preexisting humoural immune response against NY-ESO-1 received ipilimumab at a dose of 10 mg/kg in week 1, 4, 7, 10 followed by 3-month maintenance treatment for a maximum of 48 weeks. Primary endpoint was the disease control rate (irCR, irPR or irSD) according to immune-related response criteria (irRC). Secondary endpoints included the disease control rate according to RECIST criteria, progression-free survival and overall survival (OS). Humoural and cellular immune responses against NY-ESO-1 were analysed from blood samples. - Results - Disease control rate according to irRC was 52%, irPR was observed in 36% of patients. Progression-free survival according to irRC was 7.8 months, according to RECIST criteria it was 2.9 months. Median OS was 22.7 months; the corresponding 1-year survival rate was 66.8%. Treatment-related grade 3 AEs occurred in 36% with no grade 4-5 AEs. No clear association was found between the presence of NY-ESO-1-specific cellular or humoural immune responses and clinical activity. - Conclusion - Ipilimumab demonstrated clinically relevant activity within this biomarker-defined population. NY-ESO-1 positivity, as a surrogate for a preexisting immune response against tumour antigens, might help identifying patients with a superior outcome from immune checkpoint blockade. Clinical trial information: NCT01216696 | ||
| 650 | 4 | |a Cancer/testis antigen | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Ipilimumab | |
| 650 | 4 | |a Melanoma | |
| 650 | 4 | |a NY-ESO-1 | |
| 700 | 1 | |a Zörnig, Inka |e VerfasserIn |0 (DE-588)1022346741 |0 (DE-627)716954850 |0 (DE-576)36517937X |4 aut | |
| 700 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 700 | 1 | |a Halama, Niels |d 1977- |e VerfasserIn |0 (DE-588)13087325X |0 (DE-627)507228723 |0 (DE-576)251045706 |4 aut | |
| 700 | 1 | |a Dick, Julika |d 1983- |e VerfasserIn |0 (DE-588)102042513X |0 (DE-627)691215308 |0 (DE-576)360424155 |4 aut | |
| 700 | 1 | |a Lang, Nina |d 1985- |e VerfasserIn |0 (DE-588)143835718 |0 (DE-627)655106057 |0 (DE-576)339275413 |4 aut | |
| 700 | 1 | |a Podola, Lilli |d 1975- |e VerfasserIn |0 (DE-588)137463243 |0 (DE-627)593167694 |0 (DE-576)303783818 |4 aut | |
| 700 | 1 | |a Ziegelmeier, Claudia |e VerfasserIn |0 (DE-588)1108792782 |0 (DE-627)863988415 |0 (DE-576)475484452 |4 aut | |
| 700 | 1 | |a Freitag, Angelika |e VerfasserIn |0 (DE-588)1151580295 |0 (DE-627)1011924056 |0 (DE-576)497884690 |4 aut | |
| 700 | 1 | |a Beckhove, Philipp |d 1969- |e VerfasserIn |0 (DE-588)121272842 |0 (DE-627)705350169 |0 (DE-576)292620748 |4 aut | |
| 700 | 1 | |a Enk, Alexander |d 1963- |e VerfasserIn |0 (DE-588)1032757140 |0 (DE-627)739272535 |0 (DE-576)166173517 |4 aut | |
| 700 | 1 | |a Jäger, Dirk |d 1964- |e VerfasserIn |0 (DE-588)1032507535 |0 (DE-627)738505323 |0 (DE-576)380074125 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 90(2018), Seite 122-129 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1 |
| 773 | 1 | 8 | |g volume:90 |g year:2018 |g pages:122-129 |g extent:8 |a Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2017.12.001 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0959804917314570 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190815 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 1032507535 |a Jäger, Dirk |m 1032507535:Jäger, Dirk |d 910000 |e 910000PJ1032507535 |k 0/910000/ |p 18 |y j | ||
| 998 | |g 1032757140 |a Enk, Alexander |m 1032757140:Enk, Alexander |d 910000 |d 911300 |e 910000PE1032757140 |e 911300PE1032757140 |k 0/910000/ |k 1/910000/911300/ |p 17 | ||
| 998 | |g 121272842 |a Beckhove, Philipp |m 121272842:Beckhove, Philipp |d 50000 |e 50000PB121272842 |k 0/50000/ |p 16 | ||
| 998 | |g 1151580295 |a Freitag, Angelika |m 1151580295:Freitag, Angelika |d 910000 |e 910000PF1151580295 |k 0/910000/ |p 14 | ||
| 998 | |g 1108792782 |a Ziegelmeier, Claudia |m 1108792782:Ziegelmeier, Claudia |d 910000 |e 910000PZ1108792782 |k 0/910000/ |p 9 | ||
| 998 | |g 137463243 |a Podola, Lilli |m 137463243:Podola, Lilli |d 910000 |e 910000PP137463243 |k 0/910000/ |p 7 | ||
| 998 | |g 143835718 |a Lang, Nina |m 143835718:Lang, Nina |d 910000 |d 911300 |e 910000PL143835718 |e 911300PL143835718 |k 0/910000/ |k 1/910000/911300/ |p 6 | ||
| 998 | |g 102042513X |a Dick, Julika |m 102042513X:Dick, Julika |d 910000 |d 911300 |e 910000PD102042513X |e 911300PD102042513X |k 0/910000/ |k 1/910000/911300/ |p 5 | ||
| 998 | |g 13087325X |a Halama, Niels |m 13087325X:Halama, Niels |d 910000 |d 910100 |e 910000PH13087325X |e 910100PH13087325X |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |e 910000PH129790702 |e 911300PH129790702 |k 0/910000/ |k 1/910000/911300/ |p 3 | ||
| 998 | |g 1022346741 |a Zörnig, Inka |m 1022346741:Zörnig, Inka |d 910000 |d 910100 |e 910000PZ1022346741 |e 910100PZ1022346741 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 133390934 |a Haag, Georg Martin |m 133390934:Haag, Georg Martin |d 910000 |d 910100 |e 910000PH133390934 |e 910100PH133390934 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN167144812X |e 3507172895 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["G. M. Haag, I. Zoernig, J. C. Hassel, N. Halama, J. Dick, N. Lang, L. Podola, J. Funk, C. Ziegelmeier, S. Juenger, M. Bucur, L. Umansky, C. S. Falk, A. Freitag, I. Karapanagiotou-Schenkel, P. Beckhove, A. Enk, D. Jaeger"]},"id":{"doi":["10.1016/j.ejca.2017.12.001"],"eki":["167144812X"]},"person":[{"display":"Haag, Georg Martin","family":"Haag","given":"Georg Martin","role":"aut"},{"given":"Inka","role":"aut","family":"Zörnig","display":"Zörnig, Inka"},{"role":"aut","given":"Jessica C.","family":"Hassel","display":"Hassel, Jessica C."},{"display":"Halama, Niels","family":"Halama","role":"aut","given":"Niels"},{"display":"Dick, Julika","family":"Dick","given":"Julika","role":"aut"},{"family":"Lang","given":"Nina","role":"aut","display":"Lang, Nina"},{"display":"Podola, Lilli","family":"Podola","given":"Lilli","role":"aut"},{"display":"Ziegelmeier, Claudia","role":"aut","given":"Claudia","family":"Ziegelmeier"},{"display":"Freitag, Angelika","role":"aut","given":"Angelika","family":"Freitag"},{"display":"Beckhove, Philipp","given":"Philipp","role":"aut","family":"Beckhove"},{"role":"aut","given":"Alexander","family":"Enk","display":"Enk, Alexander"},{"display":"Jäger, Dirk","family":"Jäger","given":"Dirk","role":"aut"}],"relHost":[{"corporate":[{"display":"European Organization for Research on Treatment of Cancer","role":"isb"},{"role":"isb","display":"European Association for Cancer Research"},{"role":"isb","display":"European School of Oncology"}],"titleAlt":[{"title":"EJC online"}],"pubHistory":["28.1992 -"],"id":{"issn":["1879-0852"],"eki":["266883400"],"zdb":["1468190-0"]},"part":{"year":"2018","pages":"122-129","extent":"8","volume":"90","text":"90(2018), Seite 122-129"},"recId":"266883400","disp":"Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1European journal of cancer","origin":[{"publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedKey":"1992","dateIssuedDisp":"1992-","publisher":"Elsevier ; Pergamon Press"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"title":[{"title":"European journal of cancer","title_sort":"European journal of cancer"}]}],"origin":[{"dateIssuedDisp":"5 January 2018","dateIssuedKey":"2018"}],"title":[{"title":"Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1","title_sort":"Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1"}],"note":["Gesehen am 15.08.2019"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"recId":"167144812X","physDesc":[{"extent":"8 S."}]} | ||
| SRT | |a HAAGGEORGMPHASEIITRI5201 | ||